Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any gender
• People who have been confirmed through a tissue or cell sample to have colorectal cancer (bowel cancer)
• People who have cancer that has spread to the liver, with at least one measurable area of cancer spread plus one liver tumour that can be treated with radiotherapy — but not people whose liver tumours were considered surgically removable from the start
• People who have not yet received any treatment for their cancer, or people whose cancer has come back after surgery and who have not had any anti-cancer treatment in the past 6 months, with at least 6 months passed since their last course of chemotherapy after surgery
• People who are generally well enough to carry out daily activities with little to no limitation (as rated on a standard medical scale of 0–1)
• People who are expected to live for at least 3 months
• People whose blood, liver, and kidney results fall within acceptable ranges on tests done within 7 days before screening — including healthy enough levels of red blood cells, white blood cells, and platelets; liver enzyme levels within acceptable limits; kidney function within acceptable limits; and blood clotting results within acceptable limits (confirm specific values with the trial site)
• People who are willing to take part voluntarily, sign a consent form, and attend follow-up visits

Who may not be able to join:

• People who have had another cancer in the past 3 years, except for certain fully treated skin cancers or cervical pre-cancers
• People who have cancer that has spread to the brain or the lining of the brain and is causing symptoms, unless it has been treated and has been stable and symptom-free for more than 2 months
• People who have a blocked bowel, active bowel bleeding, or a hole in the bowel wall
• People who have previously been treated with certain immune checkpoint or T-cell targeting drugs (such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapies)
• People who have an active autoimmune disease, or a history of one that could return (such as lupus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, or similar conditions), or people at high risk due to organ transplant requiring immune-suppressing medication — though people with certain mild or well-controlled conditions (such as hypothyroidism on thyroid hormone replacement, type 1 diabetes on insulin, or vitiligo or psoriasis not needing systemic treatment in the past 2 years) may still be considered
• People who currently have or have had lung inflammation, pulmonary fibrosis, or radiation-related lung disease
• People who have taken part in another clinical drug trial within the past 4 weeks (observational studies without treatment are generally acceptable)
• People who have taken immune-suppressing medications within the past 4 weeks, with some exceptions such as low-dose steroids, inhaled or topical steroids, or short-term steroids for allergies
• People who have received a live vaccine (such as a live flu vaccine) in the past 4 weeks, or who plan to receive one during the trial — injected inactivated flu vaccines are generally acceptable
• People who have had major surgery (such as brain, chest, or abdominal surgery) within the past 4 weeks, or who are expected to need major surgery during the trial
• People who have HIV, other immune deficiency conditions, or who have had an organ or stem cell transplant
• People with active hepatitis B or active hepatitis C — though carriers of hepatitis B who are stable on antiviral treatment, or people who have fully cleared hepatitis C, may be considered
• People with active tuberculosis
• People who have had a serious infection in the past 4 weeks, or an active infection requiring antibiotics in the past 2 weeks
• People with moderate to severe heart failure or poorly controlled heart rhythm problems
• People with high blood pressure that remains uncontrolled despite standard treatment (blood pressure of 160/100 mmHg or above)
• People who have had a heart attack, stroke, unstable chest pain, or mini-stroke in the past 6 months
• People who have had a serious blood clot (such as a deep vein clot or a clot in the lungs) in the past 3 months — minor clots related to medical lines or ports are generally not included in this
• People with documented neurological or psychiatric conditions such as epilepsy, dementia, or peripheral nerve disorders
• People with alcohol dependence or a history of drug misuse in the past year
• People who are pregnant or breastfeeding, or people of childbearing potential who are not using adequate contraception
• People with other significant medical, psychiatric, or laboratory abnormalities that the trial doctor believes would make participation unsafe or affect the trial results

Important: Always verify eligibility with the trial site directly before applying.